1. Home
  2. Analysis
  3. Glatiramer-acetate
  4. Injection-site-warmth

Glatiramer acetate and Injection site warmth - a phase IV clinical study of FDA data

Summary:

Injection site warmth is reported as a side effect among people who take Glatiramer acetate (glatiramer acetate), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Wellbutrin, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Injection site warmth when taking Glatiramer acetate. It is created by eHealthMe based on reports of 5,153 people who have side effects when taking Glatiramer acetate from the FDA, and is updated regularly.

What is Glatiramer acetate?

Glatiramer acetate has active ingredients of glatiramer acetate. eHealthMe is studying from 5,158 Glatiramer acetate users. Check the latest studies of Glatiramer acetate.

What is Injection site warmth?

Injection site warmth is found to be associated with 525 drugs and 699 conditions by eHealthMe. Check the latest studies of Injection site warmth.

On Jul, 18, 2026

5,153 people reported to have side effects when taking Glatiramer acetate.
Among them, 69 people (1.34%) have Injection site warmth.

Could Glatiramer acetate cause Injection site warmth?

Among these 69 people:

How long have people been on Glatiramer acetate when they have Injection site warmth? *

  • < 1 month: 66.67 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Injection site warmth when taking Glatiramer acetate? *

  • female: 86.96 %
  • male: 13.04 %

What is the age of people who have Injection site warmth when taking Glatiramer acetate? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 6.25 %
  • 30-39: 18.75 %
  • 40-49: 34.38 %
  • 50-59: 21.88 %
  • 60+: 18.75 %

What are other drugs people take besides Glatiramer acetate? *

  1. Wellbutrin: 4 people, 5.80%
  2. Vitamin D: 3 people, 4.35%
  3. Gabapentin: 2 people, 2.90%
  4. Voltaren: 2 people, 2.90%
  5. Ampyra: 2 people, 2.90%
  6. Synthroid: 2 people, 2.90%
  7. Copaxone: 2 people, 2.90%
  8. Zonegran: 1 person, 1.45%
  9. Benadryl: 1 person, 1.45%
  10. Cephalexin: 1 person, 1.45%

What are other side effects people have besides Injection site warmth? *

  1. Injection Site Erythema (redness at injection site): 52 people, 75.36%
  2. Injection Site Pain: 49 people, 71.01%
  3. Injection Site Swelling: 40 people, 57.97%
  4. Injection Site Mass: 29 people, 42.03%
  5. Injection Site Urticaria (rash of round, red welts on the skin at injection site): 21 people, 30.43%
  6. Injection Site Pruritus (severe itching at injection site): 20 people, 28.99%
  7. Injection Site Bruising: 17 people, 24.64%
  8. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 15 people, 21.74%
  9. Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 11 people, 15.94%
  10. Fatigue (feeling of tiredness): 10 people, 14.49%

What are the existing conditions these people have? *

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 37 people, 53.62%
  2. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 33 people, 47.83%
  3. Incontinence (lack of moderation or self-control): 2 people, 2.90%
  4. Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 1 person, 1.45%
  5. Scoliosis (a medical condition in which a person's spine is curved from side to side): 1 person, 1.45%
  6. Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 1 person, 1.45%

* Approximation only. Some reports may have incomplete information.

Do you take Glatiramer acetate and have Injection site warmth?

- Check whether Injection site warmth is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Glatiramer acetate:

Injection site warmth treatments and more:

How severe was Injection site warmth and when was it recovered:

Expand to all the drugs that have ingredients of glatiramer acetate:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glatiramer acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site warmth:

Browse all the conditions that are associated with Injection site warmth:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Glatiramer acetate) and Glatiramer acetate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.